BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26402513)

  • 1. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
    Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
    Matsuzono K; Sato K; Kono S; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 48(3):757-63. PubMed ID: 26402119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II).
    Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Koike M; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 47(2):487-93. PubMed ID: 26401570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS).
    Nakano Y; Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Deguchi K; Abe K
    J Alzheimers Dis; 2015; 47(3):609-17. PubMed ID: 26401696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
    Fukui Y; Hishikawa N; Ichinose J; Sato K; Nakano Y; Morihara R; Ohta Y; Yamashita T; Abe K
    Geriatr Gerontol Int; 2017 Nov; 17(11):1991-1999. PubMed ID: 28276131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
    Ohta Y; Darwish M; Hishikawa N; Yamashita T; Sato K; Takemoto M; Abe K
    Geriatr Gerontol Int; 2017 Nov; 17(11):1843-1848. PubMed ID: 28060449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.
    Tokuchi R; Hishikawa N; Matsuzono K; Takao Y; Wakutani Y; Sato K; Kono S; Ohta Y; Deguchi K; Yamashita T; Abe K
    Geriatr Gerontol Int; 2016 Apr; 16(4):440-5. PubMed ID: 25952367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
    Hishikawa N; Fukui Y; Sato K; Ohta Y; Yamashita T; Abe K
    Geriatr Gerontol Int; 2017 Oct; 17(10):1384-1391. PubMed ID: 27578455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
    Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
    Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.